What is ImmunoScape?
ImmunoScape is a pioneering company operating in the immunomics sector. It has developed a sophisticated technology platform designed for the high-resolution profiling and characterization of the human immune response. By integrating advanced techniques such as mass cytometry, single-cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools, ImmunoScape delivers novel and reproducible immune profiling information. This deep immunomics capability positions the company at the forefront of understanding complex biological systems.
How much funding has ImmunoScape raised?
ImmunoScape has raised a total of $39M across 3 funding rounds:
Unspecified
$11M
Unspecified
$14M
Other Financing Round
$14M
Unspecified (2020): $11M with participation from Utec, NPR Holdings, and Anzu Partners
Unspecified (2021): $14M led by University of Tokyo Edge Capital Partners, Anzu Partners LLC, and EDBI
Other Financing Round (2022): $14M supported by EDBI and Anzu Partners
Key Investors in ImmunoScape
Utec
UTEC is a venture capital firm associated with the University of Tokyo, specializing in early-stage startups with strong intellectual property. They manage significant capital and focus on contributing to society through technological innovation.
Anzu Partners
Anzu Partners is an investment firm that backs breakthrough technologies in sectors including life sciences. They provide strategic support and capital to help companies accelerate growth and market penetration.
EDBI
EDBI is a Singapore-based global investor focused on high-growth technology sectors. They aim to empower businesses and build sustainable legacies through strategic investments in innovative companies.
What's next for ImmunoScape?
With the recent major strategic investment, ImmunoScape is poised for accelerated growth and further development of its Deep Immunomics platform. The substantial enterprise-level funding suggests a strategic focus on scaling operations, expanding research and development initiatives, and potentially broadening its market reach. This capital infusion will likely enable ImmunoScape to enhance its analytical tools and deepen its characterization of the human immune response, solidifying its position in the competitive biotechnology landscape.
See full ImmunoScape company page
